Dunedin-based cancer diagnostics firm Pacific Edge saw its share price jump 8 percent on Friday, following a consecutive 9 percent gain on Thursday, after the company announced that its Cxbladder urine tests have been granted coverage under the United States Medicare system. The decision, which takes effect on 20 December 2026, establishes a specific reimbursement framework for the company's Triage and Triage Plus tests, setting the price per te…
Read with caution - this story is only being covered by one news source that has a ‘low factuality’ rating, which means the outlet has a history of poor reporting practices. Learn more about factuality ratings here.